Loading clinical trials...
Loading clinical trials...
A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants With Severe Asthma Who Completed the VALIANT Trial
Conditions
Interventions
Verekitug
Placebo
Locations
102
United States
Kern Research, Inc.
Bakersfield, California, United States
California Medical Research Associates Inc.
Northridge, California, United States
Integrated Research of Inland Inc
Upland, California, United States
Allergy & Asthma Clinical Research
Walnut Creek, California, United States
Allianz Research Institute
Westminster, California, United States
Advance Pharma Research
Cutler Bay, Florida, United States
Start Date
May 21, 2025
Primary Completion Date
September 1, 2027
Completion Date
September 1, 2027
Last Updated
April 2, 2026
NCT05691218
NCT03984253
NCT06681545
NCT06385236
NCT07343661
NCT06916104
Lead Sponsor
Upstream Bio Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions